Nymox Announces Two Data Presentations for Company's BPH Drug at New York American Urological Association Meeting November 6
October 26 2017 - 12:15PM
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to
announce that two data presentations of the Company's new drug
Fexapotide Triflutate will be held at the November meeting of the
American Urological Association, New York Section. The November 6
presentations at the New York AUA meeting in Havana will include a
podium presentation authored by Ronald Tutrone MD FACS, Baltimore,
MD; Mitchell Efros MD FACS, Garden City, NY; Mohammed Bidair MD,
San Diego, CA; James Bailen MD FACS, Louisville, KY; Franklin
Gaylis MD FACS, San Diego, CA; Barton Wachs MD FACS, Long Beach,
CA; Richard Levin MD FACS, Baltimore, MD; Susan Kalota MD FACS,
Tucson, AZ; Sheldon Freedman MD FACS, Las Vegas, NV; Barry Shepard
MD FACS, Garden City, NY; Jed Kaminetsky MD FACS, New York, NY;
Steven Gange MD FACS, Salt Lake City, UT; and Ivan Grunberger MD
FACS, Brooklyn, NY. The podium presentation will be presented by
Dr. Ivan Grunberger. Dr. Grunberger is the Immediate Past President
of the New York Section of the AUA.
A second Symposium presentation and panel
discussion will occur on November 6 at the AUA meeting. The
Chairperson of the Symposium will be Ronald Tutrone MD FACS of
Chesapeake Urology, Baltimore, MD. Panel members for the
Symposium will include Dr. Grunberger; Jeffrey Snyder MD FACS,
Denver, CO; and Kenneth Goldberg MD FACS, Carrollton, TX.
Further details on the November 6 presentations
at the New York AUA Meeting will be provided prior to the
meeting.
Dr. Paul Averback, CEO of Nymox said, "The
upcoming meetings and presentations at the AUA meeting November 6
will involve highly experienced and well-known BPH investigators
who participated in the trials and who will present data and
discuss results of the Fexapotide Phase 3 clinical studies. These
represent the second and third of many important communication
undertakings with the medical communities which are and will be
occurring for Fexapotide."
Nymox's lead drug Fexapotide has been in
development for over 10 years and has been tested by expert
clinical trial investigative teams in over 70 distinguished
clinical trial centers throughout the US, and has been found after
7 years of prospective placebo controlled double blind studies of
treatment of 995 U.S. men with prostate enlargement to not only
show clinically meaningful and durable relief of BPH symptoms, but
also to show a major reduction in the incidence of prostate cancer,
compared to placebo and compared to the known and expected normal
incidence of the disease. The same clinical program has also shown
in a long-term blinded placebo crossover group study an 82-95%
reduction in the number of these patients who required surgery
after they received crossover Fexapotide in the trial, as compared
to patients who did not receive Fexapotide but instead received
crossover conventional approved BPH treatments (p<.0001).
For more information please
contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forwardlooking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2016, and its Quarterly Reports.
Contact:Paul AverbackNymox
Pharmaceutical Corporation800-93NYMOXwww.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2023 to Apr 2024